Pillar Pacific Capital Management LLC lessened its stake in DexCom, Inc. (NASDAQ:DXCM) by 4.8% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 3,550 shares of the medical device company’s stock after selling 180 shares during the quarter. Pillar Pacific Capital Management LLC’s holdings in DexCom were worth $529,000 as of its most recent SEC filing.
Several other hedge funds also recently modified their holdings of DXCM. Gradient Investments LLC acquired a new position in shares of DexCom in the 2nd quarter valued at about $25,000. Virtus ETF Advisers LLC acquired a new position in shares of DexCom in the 2nd quarter valued at about $29,000. Steward Partners Investment Advisory LLC acquired a new position in shares of DexCom in the 2nd quarter valued at about $31,000. CSat Investment Advisory L.P. acquired a new position in shares of DexCom in the 2nd quarter valued at about $31,000. Finally, Wealthcare Advisory Partners LLC acquired a new position in shares of DexCom in the 2nd quarter valued at about $37,000. 96.19% of the stock is owned by institutional investors and hedge funds.
Shares of DexCom stock traded up $43.11 during mid-day trading on Thursday, reaching $196.23. 188,436 shares of the stock traded hands, compared to its average volume of 623,917. The business has a 50-day moving average of $153.97 and a 200 day moving average of $145.47. DexCom, Inc. has a fifty-two week low of $105.05 and a fifty-two week high of $178.45. The stock has a market capitalization of $14.46 billion, a PE ratio of 654.50 and a beta of 0.64. The company has a quick ratio of 5.64, a current ratio of 6.05 and a debt-to-equity ratio of 1.56.
DexCom (NASDAQ:DXCM) last announced its earnings results on Wednesday, November 6th. The medical device company reported $0.65 EPS for the quarter, beating analysts’ consensus estimates of $0.20 by $0.45. DexCom had a positive return on equity of 10.41% and a negative net margin of 13.96%. The business had revenue of $396.30 million during the quarter, compared to analysts’ expectations of $348.99 million. During the same quarter in the prior year, the firm earned $0.17 earnings per share. The business’s revenue was up 48.6% compared to the same quarter last year. On average, equities research analysts expect that DexCom, Inc. will post 0.94 EPS for the current fiscal year.
DXCM has been the subject of a number of analyst reports. BidaskClub raised DexCom from a “hold” rating to a “buy” rating in a report on Friday, November 1st. ValuEngine cut DexCom from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. UBS Group upped their price target on DexCom from $140.00 to $160.00 and gave the stock a “neutral” rating in a report on Thursday, August 1st. Oppenheimer upped their price target on DexCom from $167.00 to $180.00 in a report on Thursday, August 1st. Finally, Guggenheim raised DexCom from a “neutral” rating to a “buy” rating in a report on Thursday. Five equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $180.63.
In other DexCom news, CEO Kevin R. Sayer sold 10,000 shares of the stock in a transaction that occurred on Monday, November 4th. The stock was sold at an average price of $157.50, for a total transaction of $1,575,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Nicholas Augustinos sold 1,208 shares of the stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $145.49, for a total value of $175,751.92. The disclosure for this sale can be found here. Insiders have sold 104,014 shares of company stock valued at $16,183,576 in the last three months. Insiders own 0.88% of the company’s stock.
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Further Reading: Short Selling Stocks and Day Traders
Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.